Bionano Genomics Inc BNGO.OQ BNGO.O is expected to show a fall in quarterly revenue when it reports results on November 13 for the period ending September 30 2024
The San Diego California-based company is expected to report a 15.7% decrease in revenue to $7.854 million from $9.32 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.The company's guidance on October 10 2024, for the period ended September 30, was for revenue between $6.50 million and $6.80 million.
LSEG's mean analyst estimate for Bionano Genomics Inc is for a loss of 21 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Bionano Genomics Inc is $1.90, above its last closing price of $0.28.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jan. 1 0001 | -0.41 | -0.42 | -0.22 | Beat | 47.2 |
Mar. 31 0001 | -0.64 | -0.64 | -0.51 | Beat | 20.9 |
Jan. 1 0001 | -0.87 | -0.87 | -0.41 | Beat | 53 |
Sep. 30 2023 | -0.92 | -0.97 | -1.00 | Missed | -3.1 |
Jun. 30 2023 | -1.00 | -1.03 | -1.24 | Missed | -20 |
Mar. 31 2023 | -1.10 | -1.10 | -1.20 | Missed | -9.1 |
Dec. 31 2022 | -1.14 | -1.10 | -1.30 | Missed | -18.2 |
Sep. 30 2022 | -1.18 | -1.15 | -1.10 | Beat | 4.3 |
This summary was machine generated November 12 at 03:46 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments